219 related articles for article (PubMed ID: 34386381)
1. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
[TBL] [Abstract][Full Text] [Related]
2. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
3. Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.
Kataria BC; Mehta DS; Chhaiya SB
Indian Heart J; 2013; 65(1):24-9. PubMed ID: 23438609
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
[TBL] [Abstract][Full Text] [Related]
5. Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the U.S. FDA, EMA, and PMDA: A 20-year analysis (2001-2021).
Alipour S; Nadimi Parashkouhi S; Mojahedian M; Abbasian H
Medicine (Baltimore); 2024 Jun; 103(25):e38142. PubMed ID: 38905367
[TBL] [Abstract][Full Text] [Related]
6. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
7. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies.
Han Y; Jiang R; Li J; Wang Y; Shao R; Xie J
Clin Pharmacol Ther; 2024 Jun; 115(6):1400-1407. PubMed ID: 38429944
[TBL] [Abstract][Full Text] [Related]
9. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of cancer drug approvals in india and high-income countries.
Roy AM; Jones R; Mathew A
J Cancer Policy; 2022 Sep; 33():100349. PubMed ID: 35902067
[TBL] [Abstract][Full Text] [Related]
11. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
Nagai S; Ozawa K
Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
[TBL] [Abstract][Full Text] [Related]
12. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Br J Clin Pharmacol; 2021 Aug; 87(8):3279-3291. PubMed ID: 33511674
[TBL] [Abstract][Full Text] [Related]
13. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021.
Luo X; Du X; Li Z; Qian F; Yang Y
Clin Pharmacol Ther; 2023 Jan; 113(1):170-181. PubMed ID: 36151921
[TBL] [Abstract][Full Text] [Related]
15. What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016.
Kondo H; Saint-Raymond A; Yasuda N
Ther Innov Regul Sci; 2018 Mar; 52(2):214-219. PubMed ID: 29714521
[TBL] [Abstract][Full Text] [Related]
16. Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union.
Alnuhait M; Alshammari A; Alharbi M; AlOtaibi L; Alharbi R; Khobrani A; Alkhudair N; Alshamrani M; Alrajhi AM
Ther Innov Regul Sci; 2024 Jul; 58(4):678-686. PubMed ID: 38536660
[TBL] [Abstract][Full Text] [Related]
17. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
Nagai S
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
19. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
Noguchi A; Hanaoka H; Uyama Y
Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
[TBL] [Abstract][Full Text] [Related]
20. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
